SIP 007: Prevalence, Correlates, and Trends of HPV Infection Among Young Men Having Sex with Men

Prevalence, Correlates, and Trends of HPV Infection Among Young Men Having Sex with Men Summary Newly released ACIP guidelines for the administration of the quadrivalent HPV vaccine to young men who have sex with men (YMSM) may be an important contribution to averting HPV-related cancers in this population (e.g., head and neck cancers, anal cancer, penile cancers). Unfortunately, empirical evidence is lacking with respect to the prevalence of HPV among MSM, the prevalence of HPV sub-types among YMSM, and possible trends in prevalence as a consequence of increased vaccination of YMSM. Further, evidence is lacking regarding HPV vaccine acceptance, uptake, and series completion among YMSM. The proposed study expands upon our past study of more than 1,100 YMSM (recruited and assessed over a three-year period) recruited from STI clinics in Chicago and Los Angeles. That study collected an extensive battery of HPV-related measures (yielding more than 200 behavioral variables) from YMSM as well as type-specific HPV test results from three anatomic sites (oral, anal, and serology). The proposed study will collect this same data (behavioral and biological) from 1,100 additional YMSM this yielding a dataset representing 2,200 YMSM. Data collection will occur in the same two U.S. cities thereby allowing for trend comparisons over what will be a five-year period of time. Trend comparisons will be based on calendar year of data collection. The aims are: 1) To enroll 1,100 YMSM in a cross-sectional study designed to assess the prevalence and correlates of testing positive for HPV, and the acceptance, uptake and series completion of the HPV vaccine. 2) Using a dataset of nearly 2,200 YMSM, identify trends in HPV prevalence as a function of vaccination rates. 3) Using a dataset of 2,200 YMSM, identify HPV subtypes that occur most commonly in YMSM, stratified by Black versus non-Black race, HIV serostatus, and age dichotomized as 18 through 21 versus 22 through 26 years. 4) Using a dataset of 2,200 YMSM, determine five-year trends in HPV vaccine acceptance, uptake, and series completion among YMSM. As part of the second proposed aim we will test the following hypothesis: population prevalence of testing positive for one or more of the four HPV types covered by the vaccine will decline by 25% between wave 1 data collection (an initial cross-sectional study of approximately 1,100 YMSM) and the proposed wave 2 data collection from an additional 1,100 YMSM. With the dataset of 2,200 YMSM we will have adequate statistical power to test this hypothesis using an analysis stratified by HIV serostatus